Eli Lilly to Present Groundbreaking Oncology Data at 2026 ESMO Congress in Madrid
Eli Lilly and Company is excited to announce its participation in the upcoming 2026 European Society for Medical Oncology (ESMO) Congress, scheduled for October 23-27 in Madrid, Spain. This event will serve as a prominent platform for the company to present pioneering advancements from its oncology portfolio, especially promising new data from several key clinical trials.
Among the highlights, Lilly will feature the first Phase 1 data of sofetabart mipitecan (Sofe-M), an investigational antibody-drug conjugate targeting folate receptor alpha (FRα), specifically designed for patients battling platinum-sensitive ovarian cancer. This groundbreaking investigation combines Sofe-M with bevacizumab, with early results indicating a significant therapeutic potential that supports the ongoing Phase 3 clinical trial aimed at expanding the treatment options in this challenging area.
In addition to Sofe-M, the congress will also spotlight updated findings for olomorasib, Lilly's investigational therapy targeting KRAS G12C-mutant non-small cell lung cancer (NSCLC). A rapid oral presentation will detail a comprehensive analysis from the LOXO-RAS-20001 trial and safety lead-in results from the Phase 3 SUNRAY-01 trial, emphasizing olomorasib's efficacy in combination with chemoimmunotherapy. This drug presents promising results for patients with advanced/metastatic KRAS G12C-mutant lung cancer, showcasing a considerable potential to reshape treatment protocols in this population.
Furthermore, Lilly will share impactful updates from the Phase 3 LIBRETTO-531 study concerning selpercatinib (Retevmo), a RET kinase inhibitor, which is currently being evaluated in patients with advanced, kinase inhibitor-naïve RET-mutant medullary thyroid cancer (MTC). A proffered paper presentation will delve into the updated outcomes of selpercatinib versus cabozantinib or vandetanib, marking a vital step in understanding the treatment landscape for patients with this specific mutation.
Lastly, results from the Phase 3 postMONARCH trial regarding abemaciclib (Verzenio) will also be presented, shedding light on the overall survival rates in HR-positive, HER2-negative advanced breast cancer patients post-CDK4/6 inhibitor treatment. The updated findings reinforce the significance of tailored therapeutic strategies that enhance quality of life and survival outcomes for patients.
During the congress, Jacob Van Naarden, Executive Vice President and President of Lilly Oncology, is expected to highlight the breadth and depth of Lilly’s commitment to oncology. 'Our presence at the ESMO reflects our dedication to advancing cancer care through innovative research and therapies,' he shared. 'The data we are presenting not only represent Lilly’s scientific rigor but also mark significant milestones towards improving treatment options for those with cancer.'
For oncologists, researchers, and healthcare professionals, attending this congress will offer invaluable insights into Lilly’s evolving oncology landscape, promising more effective therapeutic avenues for various cancers. The outcomes shared at ESMO 2026 are eagerly anticipated as they have the potential to influence treatment protocols and clinical practices worldwide.
This year’s ESMO Congress is shaping up to be a landmark event, with Lilly at the forefront of these significant advances in oncology. Be sure to follow the presentations closely as they unfold, as they hold the promise of enhanced patient outcomes in the realm of cancer treatment.
Among the highlights, Lilly will feature the first Phase 1 data of sofetabart mipitecan (Sofe-M), an investigational antibody-drug conjugate targeting folate receptor alpha (FRα), specifically designed for patients battling platinum-sensitive ovarian cancer. This groundbreaking investigation combines Sofe-M with bevacizumab, with early results indicating a significant therapeutic potential that supports the ongoing Phase 3 clinical trial aimed at expanding the treatment options in this challenging area.
In addition to Sofe-M, the congress will also spotlight updated findings for olomorasib, Lilly's investigational therapy targeting KRAS G12C-mutant non-small cell lung cancer (NSCLC). A rapid oral presentation will detail a comprehensive analysis from the LOXO-RAS-20001 trial and safety lead-in results from the Phase 3 SUNRAY-01 trial, emphasizing olomorasib's efficacy in combination with chemoimmunotherapy. This drug presents promising results for patients with advanced/metastatic KRAS G12C-mutant lung cancer, showcasing a considerable potential to reshape treatment protocols in this population.
Furthermore, Lilly will share impactful updates from the Phase 3 LIBRETTO-531 study concerning selpercatinib (Retevmo), a RET kinase inhibitor, which is currently being evaluated in patients with advanced, kinase inhibitor-naïve RET-mutant medullary thyroid cancer (MTC). A proffered paper presentation will delve into the updated outcomes of selpercatinib versus cabozantinib or vandetanib, marking a vital step in understanding the treatment landscape for patients with this specific mutation.
Lastly, results from the Phase 3 postMONARCH trial regarding abemaciclib (Verzenio) will also be presented, shedding light on the overall survival rates in HR-positive, HER2-negative advanced breast cancer patients post-CDK4/6 inhibitor treatment. The updated findings reinforce the significance of tailored therapeutic strategies that enhance quality of life and survival outcomes for patients.
During the congress, Jacob Van Naarden, Executive Vice President and President of Lilly Oncology, is expected to highlight the breadth and depth of Lilly’s commitment to oncology. 'Our presence at the ESMO reflects our dedication to advancing cancer care through innovative research and therapies,' he shared. 'The data we are presenting not only represent Lilly’s scientific rigor but also mark significant milestones towards improving treatment options for those with cancer.'
For oncologists, researchers, and healthcare professionals, attending this congress will offer invaluable insights into Lilly’s evolving oncology landscape, promising more effective therapeutic avenues for various cancers. The outcomes shared at ESMO 2026 are eagerly anticipated as they have the potential to influence treatment protocols and clinical practices worldwide.
This year’s ESMO Congress is shaping up to be a landmark event, with Lilly at the forefront of these significant advances in oncology. Be sure to follow the presentations closely as they unfold, as they hold the promise of enhanced patient outcomes in the realm of cancer treatment.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.